VeraDermics Inc (MANE)
NYSEHealth CareBiotechnologySnapshot 2026-07-09
$119.60-4.25%
Close 2026-07-10 · 1-day change
Reading MANE? Create a free portfolio, then add this holding for ongoing Reports and tracking. No credit card.
Create your account →NYSEHealth CareBiotechnologySnapshot 2026-07-09
Reading MANE? Create a free portfolio, then add this holding for ongoing Reports and tracking. No credit card.
Create your account →Warn: Management is running behind on a stated commitment.
Veradermics raised capital by selling 3.8 million shares at $100 each. The company aims to keep enough cash to run until 2029. It is working to reduce losses and improve cash flow. Trial data on a new hair loss drug could boost future sales.
The company lost $29.9 million in operating income in Q1. Cash flow was negative $21.2 million in the same quarter. Analysts expect losses to continue through 2027. The stock is correcting, showing investor caution.
The market expects ongoing losses and no revenue in 2026. Our view is cautious due to the company’s cash needs and uncertain drug success.
Breaks if: failure to raise capital via public offering as planned
Complete capital raise via underwritten public offering of common stock to support company operations and growth.
Newly stated in 2026-Q1. Management completed a public offering of 3,843,790 shares at $100 per share on May 1, 2026, providing capital to support operations. This is a recent capital raise event with no prior quarters for comparison, so trajectory is newly established.
“On May 1, 2026, Veradermics closed its underwritten public offering of 3,843,790 shares at $100.00 per share.”
Breaks if: cash falls below level needed to support operations through 2029
Ensure current cash, cash equivalents, and marketable securities support operating plans through 2029.
Breaks if: trial data fails to show efficacy or safety concerns arise
Breaks if: operating losses and negative cash flow worsen beyond current levels
Address operating losses and negative cash from operations to improve financial health.
Newly stated in 2026-Q1. The company reported operating income of negative $29.9 million and cash from operations of negative $21.2 million in 2026-Q1, indicating ongoing operating losses and negative cash flow. This is a recent financial reality with no prior quarters for trend comparison, so trajectory is newly established.
“Operating income was negative $29.9 million and cash from operations was negative $21.2 million.”
Standing thesis, reviewed periodically — not a price target or advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.